Catalent and GlaxoSmithKline extend contractural agreement*

Lovaza is an omega-3 prescription medication derived from fish oil approved by the FDA to reduce very high triglycerides. The Lovaza softgels are manufactured in Catalent's St. Petersburg, Florida facility, which is part of Catalent's Oral Technologies segment.

“We value our long-term partnership with GSK and look forward to continuing that relationship,” said Dr. Aris Gennadios, Catalent's Vice President and General Manager, Pharmaceutical Softgels.